An integrative network inference approach to predict mechanisms of cancer chemoresistance.

We present an integrative general network inference methodology to infer genetic and metabolic pathways associated with oncological drug chemoresistance. This methodology is general because it can infer different kinds of networks from different kinds of data. It is integrative because it integrates model simulation in its framework and it assembles into a larger integrated network all the inferred networks. The inference model is a variational approximation of Bayesian inference for stochastic processes. We used the Bayesian framework due to its ability to incorporate prior knowledge and constraints in the inference procedure and to treat both partial data and a large amount of data whose dynamics laws are mostly unknown. We show the performance of this approach using a case study of the gemcitabine chemoresistance in pancreatic cancer cells. Our method, inferred from time series data of gene expressions and metabolites, concentrates first the network of interactions of genes responsible for the sensitivity and resistance to gemcitabine, then the metabolic network, and finally it merges the two networks into a larger network predicting the correlations between genes and metabolizing enzymes.

[1]  R. Hyde,et al.  Recent molecular advances in studies of the concentrative Na+-dependent nucleoside transporter (CNT) family: identification and characterization of novel human and mouse proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). , 2001, Molecular membrane biology.

[2]  V. Anne Smith,et al.  Evaluating functional network inference using simulations of complex biological systems , 2002, ISMB.

[3]  Elisa Giovannetti,et al.  Cellular and Pharmacogenetics Foundation of Synergistic Interaction of Pemetrexed and Gemcitabine in Human Non–Small-Cell Lung Cancer Cells , 2005, Molecular Pharmacology.

[4]  I. Rusyn,et al.  Towards high-throughput metabolomics using ultrahigh-field Fourier transform ion cyclotron resonance mass spectrometry , 2008, Metabolomics.

[5]  Thomas J. Fuchs,et al.  A high-throughput metabolomics method to predict high concentration cytotoxicity of drugs from low concentration profiles , 2011, Metabolomics.

[6]  M. Stephens,et al.  Scalable Variational Inference for Bayesian Variable Selection in Regression, and Its Accuracy in Genetic Association Studies , 2012 .

[7]  D. Hedley,et al.  Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity. , 2000, Cancer research.

[8]  Paola Lecca,et al.  Inferring biochemical reaction pathways: the case of the gemcitabine pharmacokinetics , 2012, BMC Systems Biology.

[9]  Jung-Hsien Chiang,et al.  An integrative approach to identifying cancer chemoresistance-associated pathways , 2011, BMC Medical Genomics.

[10]  D. Gillespie A General Method for Numerically Simulating the Stochastic Time Evolution of Coupled Chemical Reactions , 1976 .

[11]  Pasi Soininen,et al.  Quantitative high-throughput metabolomics: a new era in epidemiology and genetics , 2012, Genome Medicine.

[12]  M. Opper,et al.  Chapter 1 Approximate inference for continuous-time Markov processes , 2009 .

[13]  I. Voutsadakis Molecular predictors of gemcitabine response in pancreatic cancer. , 2011, World journal of gastrointestinal oncology.

[14]  Godefridus J Peters,et al.  Gemcitabine chemoresistance in pancreatic cancer: Molecular mechanisms and potential solutions , 2009, Scandinavian journal of gastroenterology.

[15]  C. Ball,et al.  Identification of genes periodically expressed in the human cell cycle and their expression in tumors. , 2002, Molecular biology of the cell.

[16]  A. Mazo,et al.  Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'-difluorodeoxycytidine- induced cytotoxicity. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  E. Giovannetti,et al.  Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer , 2010, The Pharmacogenomics Journal.

[18]  Minoru Tada,et al.  Identifying genes with differential expression in gemcitabine-resistant pancreatic cancer cells using comprehensive transcriptome analysis. , 2005, Oncology reports.

[19]  Thomas G. Dietterich What is machine learning? , 2020, Archives of Disease in Childhood.

[20]  V. Heinemann,et al.  Gemcitabine: metabolism, mechanisms of action, and self-potentiation. , 1995, Seminars in oncology.

[21]  T. Noda,et al.  Identifying Molecular Markers for Chemosensitivity to Gemcitabine in Pancreatic Cancer: Increased Expression of Interferon-Stimulated Gene 15 kd Is Associated With Intrinsic Chemoresistance , 2010, Pancreas.

[22]  Manfred Opper,et al.  Approximate Inference for Stochastic Reaction processes , 2010, Learning and Inference in Computational Systems Biology.

[23]  Jos H. Beijnen,et al.  New insights into the pharmacology and cytotoxicity of gemcitabine and 2′,2′-difluorodeoxyuridine , 2008, Molecular Cancer Therapeutics.

[24]  John R. Mackey,et al.  Human Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions , 2010, Cancers.

[25]  A. Hopkins Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.

[26]  Tetsuo Arakawa,et al.  Gemcitabine sensitivity-related mRNA expression in endoscopic ultrasound-guided fine-needle aspiration biopsy of unresectable pancreatic cancer , 2009, Journal of experimental & clinical cancer research : CR.

[27]  R. Weinshilboum,et al.  Metabolomics: a global biochemical approach to drug response and disease. , 2008, Annual review of pharmacology and toxicology.

[28]  Ben van Ommen,et al.  Transcriptomic Coordination in the Human Metabolic Network Reveals Links between n-3 Fat Intake, Adipose Tissue Gene Expression and Metabolic Health , 2011, PLoS Comput. Biol..

[29]  T. Okumura,et al.  Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells , 2007, British Journal of Cancer.

[30]  Liang Zhiyong,et al.  Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines , 2009, Molecular Cancer.

[31]  G. Gallick,et al.  Gemcitabine Resistance in Pancreatic Cancer: Picking the Key Players , 2008, Clinical Cancer Research.

[32]  Darren J. Wilkinson Stochastic Modelling for Systems Biology , 2006 .

[33]  Takashi Kimura,et al.  Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma , 2011, Journal of hepato-biliary-pancreatic sciences.

[34]  E. Mini,et al.  Cellular pharmacology of gemcitabine. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  A. Hajri,et al.  Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies. , 2009, Neoplasia.

[36]  Paola Lecca,et al.  Algorithmic Modeling Quantifies the Complementary Contribution of Metabolic Inhibitions to Gemcitabine Efficacy , 2012, PloS one.

[37]  Corrado Priami,et al.  Algorithmic systems biology , 2009, CACM.